[
  {
    "ts": null,
    "headline": "Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology",
    "summary": "Abbott (NYSE: ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of the investigational AVEIR CSP leadless pacemaker technology. The AVEIR CSP acute clinical feasibility study is the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch (LBB) area. CSP is a novel pacing approach that targets the LBB area by enabling pacing t",
    "url": "https://finnhub.io/api/news?id=35f9e64cec723f751ee6a0883774621647a2c34199c476d49a948b2539fd14d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745777700,
      "headline": "Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology",
      "id": 134115144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of the investigational AVEIR CSP leadless pacemaker technology. The AVEIR CSP acute clinical feasibility study is the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch (LBB) area. CSP is a novel pacing approach that targets the LBB area by enabling pacing t",
      "url": "https://finnhub.io/api/news?id=35f9e64cec723f751ee6a0883774621647a2c34199c476d49a948b2539fd14d8"
    }
  }
]